BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lim JT, Truong PT, Berthelet E, Pai H, Joe H, Wai E, Larsson S, Kader HA, Weinerman B, Wilson K. Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2003;57:1328-1335. [PMID: 14630270 DOI: 10.1016/s0360-3016(03)00751-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Noor MT, Seehra N, Rajput J, Sharma R, Thakur BS. Evaluation of Roles of MicroRNA-21 and MicroRNA-18a in Esophageal Squamous Cell Carcinoma and Comparison of Their Changes in Expression Post-Chemoradiotherapy. Gastroenterology Res 2020;13:107-13. [PMID: 32655727 DOI: 10.14740/gr1261] [Reference Citation Analysis]
2 Sun Y, Zhang XL, Mao QF, Liu YH, Kong L, Li MH. Elective nodal irradiation or involved-field irradiation in definitive chemoradiotherapy for esophageal squamous cell cancer: a retrospective analysis in clinical N0 patients. Curr Oncol 2018;25:e423-9. [PMID: 30464693 DOI: 10.3747/co.25.3895] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Blank S, Knebel P, Haag GM, Bruckner T, Klaiber U, Burian M, Schaible A, Sisic L, Schmidt T, Diener MK, Ott K. Immediate tumor resection in patients with locally advanced gastroesophageal adenocarcinoma with nonresponse to chemotherapy after 4 weeks of treatment versus resection after completion of chemotherapy (OPTITREAT trial, DRKS00004668): study protocol for a randomized controlled pilot trial. Pilot Feasibility Stud 2016;2:18. [PMID: 27965838 DOI: 10.1186/s40814-016-0059-x] [Reference Citation Analysis]
4 Bollschweiler E, Hölscher AH, Schmidt M, Warnecke-Eberz U. Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment. Chin J Cancer Res 2015;27:221-30. [PMID: 26157318 DOI: 10.3978/j.issn.1000-9604.2015.04.04] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
5 Blank S, Lordick F, Bader F, Burian M, Dobritz M, Grenacher L, Becker K, Weichert W, Langer R, Sisic L, Stange A, Jäger D, Büchler M, Bruckner T, Siewert J, Ott K. Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation. Gastric Cancer 2015;18:314-25. [PMID: 24722800 DOI: 10.1007/s10120-014-0367-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
6 Schmidt T, Sicic L, Blank S, Becker K, Weichert W, Bruckner T, Parakonthun T, Langer R, Büchler MW, Siewert JR, Lordick F, Ott K. Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. Br J Cancer 2014;110:1712-20. [PMID: 24569472 DOI: 10.1038/bjc.2014.94] [Cited by in Crossref: 64] [Cited by in F6Publishing: 75] [Article Influence: 8.0] [Reference Citation Analysis]
7 Adenis A, Tresch E, Dewas S, Romano O, Messager M, Amela E, Clisant S, Kramar A, Mariette C, Mirabel X. Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome. BMC Cancer 2013;13:413. [PMID: 24010566 DOI: 10.1186/1471-2407-13-413] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
8 Heger U, Bader F, Lordick F, Burian M, Langer R, Dobritz M, Blank S, Bruckner T, Becker K, Herrmann K. Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis. Gastric Cancer. 2013;Sep 1; Epub ahead of print. [PMID: 23996162 DOI: 10.1007/s10120-013-0296-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
9 Hurt CN, Nixon LS, Griffiths GO, Al-Mokhtar R, Gollins S, Staffurth JN, Phillips CJ, Blazeby JM, Crosby TD. SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer. 2011;11:466. [PMID: 22035459 DOI: 10.1186/1471-2407-11-466] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
10 Fiore FD, Lecleire S, Rigal O, Galais MP, Soussan EB, David I, Paillot B, Jacob JH, Michel P. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12(26): 4185-4190 [PMID: 16830371 DOI: 10.3748/wjg.v12.i26.4185] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.0] [Reference Citation Analysis]